EA202191061A1 - фармацевтическая композиция для перорального введения, содержащая диметиламинA или его соль - Google Patents

фармацевтическая композиция для перорального введения, содержащая диметиламинA или его соль

Info

Publication number
EA202191061A1
EA202191061A1 EA202191061A EA202191061A EA202191061A1 EA 202191061 A1 EA202191061 A1 EA 202191061A1 EA 202191061 A EA202191061 A EA 202191061A EA 202191061 A EA202191061 A EA 202191061A EA 202191061 A1 EA202191061 A1 EA 202191061A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
oral administration
salt
administration containing
containing dimethylamine
Prior art date
Application number
EA202191061A
Other languages
English (en)
Inventor
Seongkyu Kim
Deokkyu Lee
Soo-Won Kim
Jun-Mo Yang
Yoong-Sik Park
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of EA202191061A1 publication Critical patent/EA202191061A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем описании обеспечена фармацевтическая композиция для перорального введения, содержащая N-(5-(4-(4-((диметиламино)метил)-3-фенил-1H-пиразол-1-ил)пиримидин-2-иламино)-4-метокси-2-морфолинофенил)акриламид (лазертиниб) или его фармацевтически приемлемую соль в качестве активного ингредиента; и комбинацию микрокристаллической целлюлозы и маннита в качестве разбавителя.
EA202191061A 2018-10-18 2019-10-17 фармацевтическая композиция для перорального введения, содержащая диметиламинA или его соль EA202191061A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180124171A KR20200043618A (ko) 2018-10-18 2018-10-18 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
PCT/IB2019/058862 WO2020079637A1 (en) 2018-10-18 2019-10-17 Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt

Publications (1)

Publication Number Publication Date
EA202191061A1 true EA202191061A1 (ru) 2021-07-09

Family

ID=70282933

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191061A EA202191061A1 (ru) 2018-10-18 2019-10-17 фармацевтическая композиция для перорального введения, содержащая диметиламинA или его соль

Country Status (27)

Country Link
US (1) US20210322428A1 (ru)
EP (2) EP4306113A3 (ru)
JP (2) JP7369769B2 (ru)
KR (2) KR20200043618A (ru)
CN (1) CN113015521A (ru)
AR (1) AR117655A1 (ru)
AU (1) AU2019360446A1 (ru)
BR (1) BR112021007061A2 (ru)
CA (1) CA3116652A1 (ru)
DK (1) DK3866767T3 (ru)
EA (1) EA202191061A1 (ru)
ES (1) ES2968966T3 (ru)
FI (1) FI3866767T3 (ru)
HR (1) HRP20231670T1 (ru)
IL (1) IL282163A (ru)
LT (1) LT3866767T (ru)
MA (1) MA53927B1 (ru)
MX (1) MX2021004457A (ru)
PE (1) PE20211818A1 (ru)
PH (1) PH12021550687A1 (ru)
PL (1) PL3866767T3 (ru)
PT (1) PT3866767T (ru)
RS (1) RS65012B1 (ru)
SG (1) SG11202103057RA (ru)
SI (1) SI3866767T1 (ru)
TW (1) TWI831848B (ru)
WO (1) WO2020079637A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
EP4349835A1 (en) 2021-06-01 2024-04-10 Hangzhou Solipharma Co., Ltd. Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL193673B1 (pl) * 1998-07-20 2007-03-30 Smithkline Beecham Corp Bezpostaciowa sól amonowa eprosartanu,jej granulat i biologicznie ulepszony preparat oraz sposoby ich wytwarzania i zastosowanie
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
ES2359377T3 (es) * 2006-10-27 2011-05-23 Fmc Corporation Celulosa microcristalina coprocesada y alcohol de azúcar como excipiente para formulaciones de comprimidos.
JP5410290B2 (ja) 2006-10-27 2014-02-05 エフ エム シー コーポレーション 共処理組成物とその製造方法、打錠可能な錠剤処方物、錠剤の製造方法及び錠剤
WO2013016694A2 (en) * 2011-07-27 2013-01-31 Cornell University Methods for rna detection and quantification
KR20140063808A (ko) 2011-09-14 2014-05-27 셀진 코포레이션 시클로프로판카르복실 산｛２-[(１s)-１-(３-에톡시-４-메톡시-페닐)-２-메탄술포닐-에틸]-３-옥소-２,３-디하이드로-１h-이소인돌-４-일｝-아마이드의 제제
CN104039319B (zh) 2011-11-29 2017-12-29 吉利德制药有限责任公司 用于治疗hcv的组合物和方法
WO2014175986A2 (en) * 2013-04-23 2014-10-30 RevOrtho LLC A method and system for modular hip resurfacing
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
SG11201701960XA (en) * 2014-10-13 2017-04-27 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
KR102606253B1 (ko) 2014-12-16 2023-11-27 시그날 파마소티칼 엘엘씨 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
CN107847448A (zh) 2015-05-22 2018-03-27 诺华股份有限公司 药物组合物
KR102488488B1 (ko) 2015-10-07 2023-01-12 쿄와 기린 가부시키가이샤 아릴알킬아민 화합물 함유 의약 조성물
CA3019391A1 (en) 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物

Also Published As

Publication number Publication date
SI3866767T1 (sl) 2024-02-29
AR117655A1 (es) 2021-08-25
WO2020079637A1 (en) 2020-04-23
ES2968966T3 (es) 2024-05-14
JP2024016052A (ja) 2024-02-06
EP3866767A4 (en) 2022-07-20
DK3866767T3 (da) 2024-01-29
US20210322428A1 (en) 2021-10-21
JP2022504943A (ja) 2022-01-13
CN113015521A (zh) 2021-06-22
FI3866767T3 (fi) 2024-01-30
SG11202103057RA (en) 2021-05-28
KR20210061457A (ko) 2021-05-27
WO2020079637A9 (en) 2020-07-23
TW202034903A (zh) 2020-10-01
EP3866767B1 (en) 2023-11-29
BR112021007061A2 (pt) 2021-07-20
HRP20231670T1 (hr) 2024-03-15
PL3866767T3 (pl) 2024-04-02
CA3116652A1 (en) 2020-04-23
EP3866767A1 (en) 2021-08-25
EP4306113A2 (en) 2024-01-17
EP4306113A3 (en) 2024-02-14
MA53927B1 (fr) 2023-12-29
PT3866767T (pt) 2024-01-18
IL282163A (en) 2021-05-31
RS65012B1 (sr) 2024-01-31
PH12021550687A1 (en) 2022-02-14
LT3866767T (lt) 2023-12-27
AU2019360446A1 (en) 2021-04-22
TWI831848B (zh) 2024-02-11
JP7369769B2 (ja) 2023-10-26
PE20211818A1 (es) 2021-09-14
MA53927A (fr) 2021-09-15
KR20200043618A (ko) 2020-04-28
MX2021004457A (es) 2021-07-07

Similar Documents

Publication Publication Date Title
EA202191061A1 (ru) фармацевтическая композиция для перорального введения, содержащая диметиламинA или его соль
CY1119663T1 (el) Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
EA201391018A1 (ru) Препараты иммуносупрессантов
RS53201B (en) BENDAMUSTIN ORAL DOSAGE FORMS
EA202290017A1 (ru) Фармацевтическая комбинация, содержащая селективный агонист рецептора s1p1
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EA201692298A1 (ru) Производные карбоксамидов
EA202092159A1 (ru) Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
EA202190621A1 (ru) Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты
EA202091293A1 (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
MX2022003830A (es) Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo.
EA202191302A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА Mcl-1 И МИДОСТАУРИНА, ЕЕ ПРИМЕНЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
RU2446158C2 (ru) Замещенные изоиндолы в качестве ингибиторов васе и их применение
UA132547U (uk) Лікарський засіб знеболювальної та спазмолітичної дії
EA202090982A1 (ru) Производные бензимидазола и варианты их применения